About the Authors
- David Ho
-
Contributed equally to this work with: David Ho, Li Chen
Affiliation Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
- Li Chen
-
Contributed equally to this work with: David Ho, Li Chen
Affiliation Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
- Xin Zhao
-
Affiliation Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
- Nicquanna Durham
-
Affiliation Cytokinetics, Inc., South San Francisco, California, United States of America
- Malar Pannirselvam
-
Affiliation Cytokinetics, Inc., South San Francisco, California, United States of America
- Dorothy E. Vatner
-
Affiliation Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
- David J. Morgans
-
Affiliation Cytokinetics, Inc., South San Francisco, California, United States of America
- Fady I. Malik
-
Affiliation Cytokinetics, Inc., South San Francisco, California, United States of America
- Stephen F. Vatner
-
* E-mail: vatnersf@umdnj.edu
Affiliations CV Dynamics, Inc., North Brunswick, New Jersey, United States of America, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
- You-Tang Shen
-
Affiliations CV Dynamics, Inc., North Brunswick, New Jersey, United States of America, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey, United States of America
Competing Interests
FIM and DJM are employees and stockholders of Cytokinetics, Inc. SFV and YTS are employees and stockholders of CV Dynamics, Inc. Cytokinetics holds the patent of the smooth muscle myosin inhibitor CK-2019165 (U.S. Patent publication 2009-0275537 A1). At the current time, there are no products related to this work in clinical development or on the market to declare. CV Dynamics has no patent rights or financial interest in product development. This does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: SFV DH YTS. Performed the experiments: DH LC YTS XZ ND MP. Analyzed the data: SFV DH LC YTS DEV ND MP. Contributed reagents/materials/analysis tools: FIM DJM ND MP. Wrote the paper: DH SVF DEV.